Identifying fusion genes can significantly impact cancer treatment options. For instance, the presence of the BCR-ABL fusion gene in chronic myeloid leukemia (CML) patients has led to the development of targeted therapies like imatinib, a tyrosine kinase inhibitor. Similarly, the detection of the EML4-ALK fusion in non-small cell lung cancer (NSCLC) patients can guide the use of ALK inhibitors, offering personalized treatment strategies.
